Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation-Reference-Cited by-同舟云学术

Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation

Published:2021-07-28 Issue:10 Volume:56 Page:3209-3216
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Landmesser Katherine B.¹,Autry Elizabeth B.¹²^ORCID,Gardner Brian M.¹²,Bosko Katherine A.²,Schadler Aric²³,Kuhn Robert J.¹²^ORCID

Affiliation:

1. Department of Pharmacy Kentucky Children's Hospital Lexington Kentucky USA

2. Department of Pharmacy The University of Kentucky College of Pharmacy Lexington Kentucky USA

3. Department of Pediatrics Kentucky Children's Hospital Lexington Kentucky USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.25569

Reference21 articles.

1. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection

2. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry

3. Cystic Fibrosis Pulmonary Guidelines

4. The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome

5. Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis;Therapeutic Drug Monitoring;2023-04

2. A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation;Antimicrobial Agents and Chemotherapy;2022-05-17

3. Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis;2022-01-03